| Name | Title | Contact Details |
|---|
Gen Trak (Main) is a Liberty, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Allen Davis and Associates is a King Of Prussia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genoa is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (Aerodone™) for the treatment of IPF. With offices in Seattle and San Diego, Genoa`s experienced clinical and inhaled product development team is rapidly advancing Aerodone for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.
Chiesi USA, Inc., headquartered in Cary, NC, is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company’s strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company’s focus areas; and generate revenues by marketing approved generic products through the Company’s wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A.
Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth. Recent discoveries have transformed our understanding of the role of exosomes in the body. We now know that these natural, cell-derived vesicles can act as a potent and safe delivery system for multiple therapeutic payloads. Recognizing the enormous potential of exosomes, Codiak is applying leading-edge translational science and rigorous drug development to build a pipeline of candidates with broad utility and the capacity to address currently “undruggable” targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas. At Codiak, we are working to create a major shift in the development of tomorrow`s medicines through scientific ambition, remarkable ingenuity and deep passion for improving patients` lives. Located in the heart of Boston`s biotechnology hub in Cambridge, Massachusetts, we are advancing a bold vision by tapping into the unique talents of a varied pool of individuals who together are achieving truly exceptional work.